Accordingly, [51] proposed a strategy of improving glycolysis as a therapeutic target for Parkinson’s disease, by enhancing kinase activity of intracellular Pgk1 by Terazosin could promote energy production to delay the course of PD. The gene discussed is PGK1; the disease is Parkinson disease.